AAAAAA
Results:
1-13
|
Results: 13
Authors:
GRIEBEL G
CURET O
PERRAULT G
SANGER DJ
Citation: G. Griebel et al., BEHAVIORAL-EFFECTS OF PHENELZINE IN AN EXPERIMENTAL-MODEL FOR SCREENING ANXIOLYTIC AND ANTI-PANIC DRUGS - CORRELATION WITH CHANGES IN MONOAMINE-OXIDASE ACTIVITY AND MONOAMINE LEVELS, Neuropharmacology, 37(7), 1998, pp. 927-935
Authors:
AUBIN N
CURET O
DEFFOIS A
CARTER C
Citation: N. Aubin et al., ASPIRIN AND SALICYLATE PROTECT AGAINST MPTP-INDUCED DOPAMINE DEPLETION IN MICE, Journal of neurochemistry, 71(4), 1998, pp. 1635-1642
Authors:
HADDJERI N
DEMONTIGNY C
CURET O
BLIER P
Citation: N. Haddjeri et al., EFFECT OF THE REVERSIBLE MONOAMINE OXIDASE-A INHIBITOR BEFLOXATONE ONTHE RAT 5-HYDROXYTRYPTAMINE NEUROTRANSMISSION, European journal of pharmacology, 343(2-3), 1998, pp. 179-192
Authors:
SCHOEMAKER H
CLAUSTRE Y
FAGE D
ROUQUIER L
CHERGUI K
CURET O
OBLIN A
GONON F
CARTER C
BENAVIDES J
SCATTON B
Citation: H. Schoemaker et al., NEUROCHEMICAL CHARACTERISTICS OF AMISULPRIDE, AN ATYPICAL DOPAMINE D-2 D-3 RECEPTOR ANTAGONIST WITH BOTH PRESYNAPTIC AND LIMBIC SELECTIVITY/, The Journal of pharmacology and experimental therapeutics, 280(1), 1997, pp. 83-97
Authors:
CANNMOISAN C
CAROFF J
LEBRAS P
GIRIN E
CURET O
GANDON JM
Citation: C. Cannmoisan et al., MEASUREMENT OF 3,4-DIHYDROXYPHENYL ETHYLENE-GLYCOL (DOPEG) IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION, Journal of liquid chromatography & related technologies, 19(19), 1996, pp. 3119-3124
Authors:
LUTHRINGER R
DAGO KT
PATAT A
CAILLE P
CURET O
DURIEU G
RINAUDO G
TOUSSAINT M
GRANIER LA
MACHER JP
Citation: R. Luthringer et al., PHARMACOELECTROENCEPHALOGRAPHIC PROFILE OF BEFLOXATONE, A NEW REVERSIBLE MAO-A INHIBITOR, IN HEALTHY-SUBJECTS, Neuropsychobiology, 34(2), 1996, pp. 98-105
Authors:
PATAT A
LECOZ F
DUBRUC C
GANDON JM
DURRIEU G
CIMAROSTI I
JEZEQUEL S
CURET O
ZIELENIUK I
ALLAIN H
ROSENZWEIG P
Citation: A. Patat et al., PHARMACODYNAMICS AND PHARMACOKINETICS OF 2 DOSE REGIMENS OF BEFLOXATONE, A NEW REVERSIBLE AND SELECTIVE MONOAMINE-OXIDASE INHIBITOR, AT STEADY-STATE IN HEALTHY-VOLUNTEERS, Journal of clinical pharmacology, 36(3), 1996, pp. 216-229
Authors:
CURET O
DAMOISEAU G
AUBIN N
SONTAG N
ROVEI V
JARREAU FX
Citation: O. Curet et al., BEFLOXATONE, A NEW REVERSIBLE AND SELECTIVE MONOAMINE OXIDASE-A INHIBITOR .1. BIOCHEMICAL PROFILE, The Journal of pharmacology and experimental therapeutics, 277(1), 1996, pp. 253-264
Authors:
PATAT A
GANDON JM
DURRIEU G
LECOZ F
CURET O
CIMAROSTI I
ALLAIN H
Citation: A. Patat et al., EFFECTS OF SINGLE AND MULTIPLE DOSES OF A NEW REVERSIBLE MAO-A INHIBITOR, BEFLOXATONE, ON PSYCHOMOTOR PERFORMANCE AND MEMORY IN HEALTHY-SUBJECTS, Human psychopharmacology, 10(2), 1995, pp. 111-125
SELECTIVE AND POTENT MONOAMINE-OXIDASE TYPE-B INHIBITORS - 2-SUBSTITUTED 5-ARYLTETRAZOLE DERIVATIVES
Authors:
LEBRETON L
CURET O
GUEDDARI S
MAZOUZ F
BERNARD S
BURSTEIN C
MILCENT R
Citation: L. Lebreton et al., SELECTIVE AND POTENT MONOAMINE-OXIDASE TYPE-B INHIBITORS - 2-SUBSTITUTED 5-ARYLTETRAZOLE DERIVATIVES, Journal of medicinal chemistry, 38(24), 1995, pp. 4786-4792
Authors:
PATAT A
LECOZ F
GANDON JM
BECK A
DURRIEU G
CURET O
ALLAIN H
Citation: A. Patat et al., USE OF FREE DHPG PLASMA-LEVELS TO ASSESS EQUIPOTENCY OF 2 DOSAGE REGIMENS OF BEFLOXATONE, A REVERSIBLE MAO-A INHIBITOR, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 146-146
Authors:
ROVEI V
CAILLE D
CURET O
EGO D
JARREAU FX
Citation: V. Rovei et al., BIOCHEMICAL PHARMACOLOGY OF BEFLOXATONE (MD370503), A NEW POTENT REVERSIBLE MAO-A INHIBITOR, Journal of neural transmission. Supplementum, (41), 1994, pp. 339-347
Authors:
CURET O
DAMOISEAU G
LABAUNE JP
ROVEL V
JARREAU FX
Citation: O. Curet et al., EFFECTS OF BEFLOXATONE, A NEW POTENT REVERSIBLE MAO-A INHIBITOR, ON CORTEX AND STRIATUM MONOAMINES IN FREELY MOVING RATS, Journal of neural transmission. Supplementum, (41), 1994, pp. 349-355
Risultati:
1-13
|